Moderna News - August 2026
🔴 Moderna is trading 6% down today after upsized $2.6 billion note offering raises dilution concerns
Moderna is trading 5.59% down at $134.79 after pricing an upsized $2.6 billion private placement of convertible senior notes due 2032, raising dilution...
Moderna Upgraded by Wolfe Research, Citing Phase 3 Cancer Vaccine Success
Wolfe Research upgraded Moderna from Underperform to Peer Perform. The rating change follows a successful Phase 3 trial for intismeran, a personalized cancer...
🟢 Moderna is trading 11% up today after positive Phase 3 melanoma-vaccine results
Moderna is trading at $153.71 (+10.67%) as investors extend the sharp repricing after its August 19 Phase 3 melanoma-vaccine results with Merck showed reduced...
🟢 Moderna is trading 12.41% up today after recovering from August 20’s 23.55% drop
Moderna is trading $149.86 (+12.41%) after recovering from the August 20 profit-taking decline. • The decline was 23.55%, following the prior session’s...
🟢 Moderna is trading 10.23% up today after a 23.55% fall on August 20 following profit-taking
Moderna is trading at $146.96, up 10.23%, rebounding after heavy profit-taking following its 176.97% surge on August 19. - Shares fell 23.55% to $133.32 on...
🟢 Moderna is trading 8.5% up today after a 23.55% fall on August 20
Moderna is trading at $144.62, up +8.47%, rebounding after falling 23.55% to $133.32 on August 20. - No clear new company-specific catalyst was identified for...
🔴 Moderna is trading 18% down today after profit-taking from August 19 surge
Moderna is trading at $143.77 (-17.55%) after apparent profit-taking following its August 19 surge. - Shares surged 176.97% on August 19 to $174.38. - The...
🔴 Moderna is trading 11.2% down in pre-market after apparent profit-taking following August 19's 176.97% surge
Moderna is trading 11.2% down at $154.91 after investors appeared to take profits following its 176.97% regular-session surge on August 19. - The rally...
🟢 Moderna is trading 11.26% up in after-hours trading after positive Phase 3 melanoma vaccine results
Moderna is trading at $194.02 (+11.26%) after the company and Merck reported positive Phase 3 results for their personalized mRNA melanoma vaccine. -...
Moderna's Stock Doubles on Cancer Vaccine Breakthrough — But Can a Company Burning Cash Grow Into a $50 Billion Valuation?
Shares of Moderna surged as much as 104.8% to $128.92 Wednesday after the company and partner Merck announced that their personalized mRNA cancer vaccine hit...
🟢 Moderna is trading 102.38% up today after Phase 3 melanoma trial success
Moderna is trading 102.38% up at $128.92 after its personalized mRNA cancer vaccine, developed with Merck, met the primary recurrence-free-survival endpoint in...
🟢 Moderna is trading 4.09% up today after FDA approval of first mRNA flu vaccine
Moderna is trading 4.09% up now at $63.05 after renewed attention to the FDA’s approval of mFlusiva, its first mRNA-based seasonal flu vaccine. - Approved for...
Moderna's First mRNA Flu Shot Clears the FDA — But Can It Actually Crack a Market Dominated by Entrenched Giants?
Shares surged +6.2% to $57.19 after the FDA approved Moderna's seasonal mRNA flu vaccine for adults 50 and older — the first influenza shot ever built on mRNA...
🟢 Moderna is trading 6.3% up today after FDA approves mFlusiva
Moderna is trading at $57.19, up +6.26%, on August 7, 2026, after the FDA approved mFlusiva, its seasonal mRNA flu vaccine for adults aged 50 and older. - The...
🟢 Moderna is trading 4% up today on mRNA flu vaccine FDA focus and improved cost controls
Moderna is trading 4% up at $58.53 in pre-market as traders focus on the upcoming FDA decision for its mRNA-1010 flu vaccine and recently improved Q2 cost...